Dr. Marc Carrier, MD
Claim this profileUniversity of Ottawa
Studies Intrapericardial Thrombosis
Studies Arterial Thromboembolic Disease
6 reported clinical trials
8 drugs studied
Clinical Trials Marc Carrier, MD is currently running
Anticoagulation Strategies
for Blood Clots in Cancer Patients
Patients with cancer are prone to have blood clots, which are usually treated with blood thinners. The main complication of blood thinners is bleeding. This is especially a concern when the number of platelets in the blood is lower than 50,000 per microliter. The role of platelets is to stop bleeding, so when the number of platelets is low, patients are at a higher risk of bleeding. Cancer patients are prone to have lower platelet numbers due to cancer therapies and/or cancer itself. It is not clear what the best treatment is for cancer patients who need blood thinners for a blood clot but have low platelet counts. The investigators plan to do a small study called a pilot study to help plan for a larger study in such patients. In the pilot study, investigators will include 50 patients with cancer, low platelet counts, and a blood clot diagnosed within 4 weeks. Patients will be randomly assigned to one of the two treatment strategies: the full dose of blood thinners along with platelet transfusion or a reduced dose of blood thinners without platelet transfusion. The investigators will follow all patients for 90 days. If this pilot study is successful, it will help lead to a much larger trial, which will provide important information on the best treatment strategy in these patients.
Recruiting5 awards Phase 44 criteria
Surveillance vs. Rivaroxaban
for Pulmonary Embolism
The clinical significance of pulmonary embolism (PE) limited to the subsegmental pulmonary arteries, so called isolated subsegmental pulmonary embolism (SSPE), remains controversial. Whether isolated SSPE represents "true" PE, a clinically more benign form of PE, a physiologic lung clearing process, or a false positive result (artifact) is currently unclear and hence, whether patients with isolated SSPE benefit from anticoagulant treatment is uncertain. Despite growing evidence from observational studies that withholding anticoagulation may be a safe option in selected patients with isolated SSPE (i.e., those without concomitant deep vein thrombosis, cancer, etc.), most patients with isolated SSPE receive anticoagulant treatment, which is associated with an increased risk of bleeding. The overall objective of the randomized controlled SAFE-SSPE trial is to evaluate the efficacy and safety of clinical surveillance without anticoagulation compared to anticoagulation treatment in low-risk patients with isolated SSPE.
Recruiting2 awards Phase 43 criteria
More about Marc Carrier, MD
Clinical Trial Related2 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Marc Carrier, MD has experience with
- Rivaroxaban
- Dalteparin
- Enoxaparin
- Tinzaparin
- Heparin
- Placebo
Breakdown of trials Marc Carrier, MD has run
Intrapericardial Thrombosis
Arterial Thromboembolic Disease
Venous Thromboembolism
Deep Vein Thrombosis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Marc Carrier, MD specialize in?
Marc Carrier, MD focuses on Intrapericardial Thrombosis and Arterial Thromboembolic Disease. In particular, much of their work with Intrapericardial Thrombosis has involved treating patients, or patients who are undergoing treatment.
Is Marc Carrier, MD currently recruiting for clinical trials?
Yes, Marc Carrier, MD is currently recruiting for 5 clinical trials in the USA. If you're interested in participating, you should apply.
Are there any treatments that Marc Carrier, MD has studied deeply?
Yes, Marc Carrier, MD has studied treatments such as Rivaroxaban, Dalteparin, Enoxaparin.
What is the best way to schedule an appointment with Marc Carrier, MD?
Apply for one of the trials that Marc Carrier, MD is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.